Interferon alpha-induced pharmacodynamic markers
AssigneeMedImmune, LLC
InventorsYihong Yao, Bahija Jallal, Ricardo Cibotti, Anthony Coyle, Peter Kiener
Life of this patent
Estimating the term…
Loading patent…
AssigneeMedImmune, LLC
InventorsYihong Yao, Bahija Jallal, Ricardo Cibotti, Anthony Coyle, Peter Kiener
Estimating the term…
The present invention encompasses type-1 IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.
1-225. (canceled)
A method of treating a patient having a type I IFN or an IFNα-mediated disease or disorder comprising:
A method of neutralizing a type I IFN or IFNα-inducible PD marker expression profile in a patient in need thereof, comprising:
A method of identifying a patient as a candidate for a therapeutic agent that binds to and modulates IFNα activity comprising:
A set of probes comprising:
Dependencies are inferred from the claim text.